Top

Published in:

Open Access 01-10-2019 | Review

Molecular mechanisms of EBV-driven cell cycle progression and oncogenesis

Authors: Huali Yin, Jiani Qu, Qiu Peng, Runliang Gan

Published in: Medical Microbiology and Immunology | Issue 5/2019

Abstract

The early stage of oncogenesis is linked to the disorder of the cell cycle. Abnormal gene expression often leads to cell cycle disorders, resulting in malignant transformation of human cells. Epstein–Barr virus (EBV) is associated with a diverse range of human neoplasms, such as malignant lymphoma, nasopharyngeal carcinoma and gastric cancer. EBV mainly infects human lymphocytes and oropharyngeal epithelial cells. EBV is latent in lymphocytes for a long period of time, is detached from the cytoplasm by circular DNA, and can integrate into the chromosome of cells. EBV expresses a variety of latent genes during latent infection. The interaction between EBV latent genes and oncogenes leads to host cell cycle disturbances, including the promotion of G₁/S phase transition and inhibition of cell apoptosis, thereby promoting the development of EBV-associated neoplasms. Molecular mechanisms of EBV-driven cell cycle progression and oncogenesis involve diverse genes and signal pathways. Here, we review the molecular mechanisms of EBV-driven cell cycle progression and promoting oncogenesis.

Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–674. https://doi.org/10.1016/j.cell.2011.02.013 CrossRefPubMed

Young LS, Yap LF, Murray PG (2016) Epstein–Barr virus: more than 50 years old and still providing surprises. Nat Rev Cancer 16(12):789–802. https://doi.org/10.1038/nrc.2016.92 CrossRefPubMed

Rochford R, Moormann AM (2015) Burkitt’s Lymphoma. Curr Top Microbiol Immunol 390(Pt 1):267–285. https://doi.org/10.1007/978-3-319-22822-8_11 CrossRefPubMed

Farrell K, Jarrett RF (2011) The molecular pathogenesis of Hodgkin lymphoma. Histopathology 58(1):15–25. https://doi.org/10.1111/j.1365-2559.2010.03705.x CrossRefPubMed

Arvey A, Ojesina AI, Pedamallu CS, Ballon G, Jung J, Duke F et al (2015) The tumor virus landscape of AIDs-related lymphomas. Blood 125(20):e14–e22CrossRefPubMedPubMedCentral

Dharnidharka VR, Webster AC, Martinez OM, Preiksaitis JK, Leblond V, Choquet S (2016) Post-transplant lymphoproliferative disorders. Nat Rev Dis Primers 2:15088. https://doi.org/10.1038/nrdp.2015.88 CrossRefPubMed

Healy JA, Dave SS (2015) The role of EBV in the pathogenesis of diffuse large B cell lymphoma. Curr Top Microbiol Immunol 390(Pt 1):315–337. https://doi.org/10.1007/978-3-319-22822-8_13 CrossRefPubMed

Cho J, Kim SJ, Park S, Yoo KH, Ki CS, Ko Y, Kim WS (2018) Significance of circulating Epstein–Barr virus DNA monitoring after remission in patients with extranodal natural killer T cell lymphoma. Ann Hematol 97(8):1427–1436. https://doi.org/10.1007/s00277-018-3313-x CrossRefPubMed

Teow SY, Yap HY, Peh SC (2017) Epstein–Barr virus as a promising immunotherapeutic target for nasopharyngeal carcinoma treatment. J Pathog 2017:7349268. https://doi.org/10.1155/2017/7349268 CrossRefPubMedPubMedCentral

10.

Chen XZ, Chen H, Castro FA, Hu JK, Brenner H (2015) Epstein–Barr virus infection and gastric cancer: a systematic review. Medicine 94(20):e792. https://doi.org/10.1097/MD.0000000000000792 CrossRefPubMedPubMedCentral

11.

Dai Y, Tang Y, He F, Zhang Y, Cheng A, Gan R, Wu Y (2012) Screening and functional analysis of differentially expressed genes in EBV-transformed lymphoblasts. Virol J 9:77–81. https://doi.org/10.1186/1743-422X-9-77 CrossRefPubMedPubMedCentral

12.

Tang Y, Luo C, Cheng A, Lu S, Xu J, Fu T, Gan R (2014) Expression of latent membrane proteins in Epstein Barr virus-transformed lymphocytes in vitro. Mol Med Rep 10(2):1117–1121. https://doi.org/10.3892/mmr.2014.2313 CrossRefPubMed

13.

Gan R, Yin Z, Liu T, Wang L, Tang Y, Song Y (2003) Cyclosporine A effectively inhibits graft-versus-host disease during development of Epstein–Barr virus-infected human B cell lymphoma in SCID mouse. Cancer Sci 94(9):796–801. https://doi.org/10.1111/j.1349-7006.2003.tb01521.x CrossRefPubMed

14.

Zhang Y, Peng X, Tang Y, Gan X, Wang C, Xie L et al (2016) Identification of IgH gene rearrangement and immunophenotype in an animal model of Epstein–Barr virus-associated lymphomas. J Med Virol 88(10):1804–1813. https://doi.org/10.1002/jmv.24526 CrossRefPubMed

15.

De Leo A, Arena G, Stecca C, Raciti M, Mattia E (2011) Resveratrol inhibits proliferation and survival of Epstein Barr virus-infected Burkitt’s lymphoma cells depending on viral latency program. Mol Cancer Res 9(10):1346–1355. https://doi.org/10.1158/1541-7786 CrossRefPubMed

16.

Kozireva S, Rudevica Z, Baryshev M, Leonciks A, Kashuba E, Kholodnyuk I (2018) Upregulation of the chemokine receptor CCR2B in Epstein–Barr virus-positive Burkitt lymphoma cell lines with the latency III program. Viruses. https://doi.org/10.3390/v10050239 CrossRefPubMedPubMedCentral

17.

Tsao SW, Tsang CM, To KF, Lo KW (2015) The role of Epstein–Barr virus in epithelial malignancies. J Pathol 235(2):323–333. https://doi.org/10.1002/path.4448 CrossRefPubMed

18.

Wang LW, Jiang S, Gewurz BE (2017) Epstein–Barr virus LMP1-mediated oncogenicity. J Virol 91(21):e01718–e01716. https://doi.org/10.1128/JVI.01718-16 CrossRefPubMedPubMedCentral

19.

Hu LF, Zabarovsky ER, Chen F, Cao SL, Ernberg I, Klein G, Winberg G (1991) Isolation and sequencing of the Epstein–Barr virus BNLF-1 gene (LMP1) from a Chinese nasopharyngeal carcinoma. J Gen Virol 72(10):2399–2409. https://doi.org/10.1099/0022-1317-72-10-2399 CrossRefPubMed

20.

Sueur C, Lupo J, Mas P, Morand P, Boyer V (2014) Difference in cytokine production and cell cycle progression induced by Epstein–Barr virus LMP1 deletion variants in Kmh2, a Hodgkin lymphoma cell line. Virol J 11:94. https://doi.org/10.1186/1743-422X-11-94 CrossRefPubMedPubMedCentral

21.

Xie P, Hostager BS, Bishop GA (2004) Requirement for TRAF3 in signaling by LMP1 but not CD40 in B lymphocyte. J Exp Med 199(5):661–671. https://doi.org/10.1084/jem.20031255 CrossRefPubMedPubMedCentral

22.

Mainou BA, Everly DN Jr, Raab-Traub N (2007) Unique signaling properties of CTAR1 in LMP1-mediated transformation. J Virol 81(18):9680–9692. https://doi.org/10.1128/JVI.01001-07 CrossRefPubMedPubMedCentral

23.

Ding L, Li L, Yang J, Zhou S, Li W, Tang M et al (2007) Latent membrane protein 1 encoded by Epstein–Barr virus induces telomerase activity via p16^INK4A/Rb/E2F1 and JNK signaling pathways. J Med Virol 79(8):1153–1163. https://doi.org/10.1002/jmv.20896 CrossRefPubMed

24.

Eliopoulos AG, Young LS (1998) Activation of the c-Jun N-terminal kinase (JNK) pathway by the Epstein–Barr virus-encoded latent membrane protein 1 (LMP1). Oncogene 16(13):1731–1742. https://doi.org/10.1038/sj.onc.1201694 CrossRefPubMed

25.

Wan J, Sun L, Mendoza JW, Chui YL, Huang DP, Chen ZJ et al (2004) Elucidation of the c-Jun N-terminal kinase pathway mediated by Epstein–Barr virus-encoded latent membrane protein 1. Mol Cell Biol 24(1): 192–199. https://doi.org/10.1128/MCB.24.1.192-199.2004 CrossRefPubMedPubMedCentral

26.

Kutz H, Reisbach G, Schultheiss U, Kieser A (2008) The c-Jun N-terminal kinase pathway is critical for cell transformation by the latent membrane protein 1 of Epstein–Barr virus. Virology 371(2):246–256. https://doi.org/10.1016/j.virol.2007.09.044 CrossRefPubMed

27.

Tsai SC, Lin SJ, Lin CJ, Chou YC, Lin JH, Yeh TH et al (2013) Autocrine CCL3 and CCL4 induced by the oncoprotein LMP1 promote Epstein–Barr virus-triggered B cell proliferation. J Virol 87(16):9041–9052. https://doi.org/10.1128/JVI.00541-13 CrossRefPubMedPubMedCentral

28.

Hömig-Hölzel C, Hojer C, Rastelli J, Casola S, Strobl LJ, Müller W et al (2008) Constitutive CD40 signaling in B cells selectively activates the noncanonical NF-kappaB pathway and promotes lymphomagenesis. J Exp Med 205(6):1317–1329. https://doi.org/10.1084/jem.20080238 CrossRefPubMedPubMedCentral

29.

Siouda M, Frecha C, Accardi R, Yue J, Cuenin C, Gruffat H et al (2014) Epstein–Barr virus down-regulates tumor suppressor DOK1 expression. PLoS Pathog 10(5):e1004125. https://doi.org/10.1371/journal.ppat.1004125 CrossRefPubMedPubMedCentral

30.

Lo AK, Lo KW, Ko CW, Young LS, Dawson CW (2013) Inhibition of the LKB1-AMPK pathway by the Epstein–Barr virus-encoded LMP1 promotes proliferation and transformation of human nasopharyngeal epithelial cells. J Pathol 230(3):336–346. https://doi.org/10.1002/path.4201 CrossRefPubMed

31.

Xiao L, Hu ZY, Dong X, Tan Z, Li W, Tang M et al (2014) Targeting Epstein–Barr virus oncoprotein LMP1-mediated glycolysis sensitizes nasopharyngeal carcinoma to radiation therapy. Oncogene 33(37):4568–4578. https://doi.org/10.1038/onc.2014.32 CrossRefPubMedPubMedCentral

32.

Mancao C, Altmann M, Jungnickel B, Hammerschmidt W (2005) Rescue of “crippled” germinal center B cells from apoptosis by Epstein–Barr virus. Blood 106(13):4339–4344. https://doi.org/10.1182/blood-2005-06-2341 CrossRefPubMedPubMedCentral

33.

Wasil LR, Wei L, Chang C, Lan L, Shair KH (2015) Regulation of DNA damage signaling and cell death responses by Epstein–Barr virus latent membrane protein 1 (LMP1) and LMP2A in nasopharyngeal carcinoma cells. J Virol 89(15):7612–7624. https://doi.org/10.1128/JVI.00958-15 CrossRefPubMedPubMedCentral

34.

Fukuda M, Kawaguchi Y (2014) Role of the immunoreceptor tyrosine-based activation motif of latent membrane protein 2A (LMP2A) in Epstein–Barr virus LMP2A-induced cell transformation. J Virol 88(9):5189–5194.https://doi.org/10.1128/JVI.03714-13 CrossRefPubMedPubMedCentral

35.

Engels N, Yigit G, Emmerich CH, Czesnik D, Schild D, Wienands J (2012) Epstein–Barr virus LMP2A signaling in statu nascendi mimics a B cell antigen receptor-like activation signal. Cell Commun Signal 10:9. https://doi.org/10.1186/1478-811X-10-9 CrossRefPubMedPubMedCentral

36.

Fotheringham JA, Coalson NE, Raab-Traub N (2012) Epstein–Barr virus latent membrane protein-2A induces ITAM/Syk- and Akt-dependent epithelial migration through αV-Integrin membrane translocation. J Virol 86(19):10308–10320. https://doi.org/10.1128/JVI.00853-12 CrossRefPubMedPubMedCentral

37.

Fukuda M, Longnecker R (2007) Epstein–Barr virus latent membrane protein 2A mediates transformation through constitutive activation of the Ras/PI3-K/Akt Pathway. J Virol 81(17):9299–9306. https://doi.org/10.1128/JVI.00537-07 CrossRefPubMedPubMedCentral

38.

Fukuda M, Longnecker R (2004) Latent membrane protein 2A inhibits transforming growth factor-β1-induced apoptosis through the phosphatidylinositol 3-kinase/Akt pathway. J Virol 78(4):1697–1705. https://doi.org/10.1128/JVI.78.4.1697-1705.2004 CrossRefPubMedPubMedCentral

39.

Swart R, Ruf IK, Samplev J, Longnecker R (2000) Latent membrane protein 2A-mediated effects on the phosphatidylinositol 3-kinase/Akt pathway. J Virol 74(22):10838–10845CrossRefPubMedPubMedCentral

40.

Bhende PM, Park SI, Lim MS, Dittmer DP, Damania B (2010) The dual PI3K/mTOR inhibitor, NVP-BEZ235, is efficacious against non-Hodgkin lymphoma. Leukemia 24(10):1781–1784. https://doi.org/10.1038/leu.2010.154 CrossRefPubMedPubMedCentral

41.

Fish K, Chen J, Longnecker R (2014) Epstein–Barr virus latent membrane protein 2A enhances MYC-driven cell cycle progression in a mouse model of B lymphoma. Blood 123(4):530–540. https://doi.org/10.1182/blood-2013-07-517649 CrossRefPubMedPubMedCentral

42.

Fish K, Sora RP, Schaller SJ, Longnecker R, Ikeda M (2017) EBV latent membrane protein 2A orchestrates p27^kip1 degradation via Cks1 to accelerate MYC-driven lymphoma in mice. Blood 130(23):2516–2526. https://doi.org/10.1182/blood-2017-07-796821 CrossRefPubMedPubMedCentral

43.

Incrocci R, Barse L, Stone A, Vagvala S, Montesano M, Subramaniam V, Swanson-Mungerson M (2017) Epstein–Barr virus latent membrane protein 2A (LMP2A) enhances IL-10 production through the activation of Bruton’s tyrosine kinase and STAT3. Virology 500:96–102. https://doi.org/10.1016/j.virol.2016.10.015 CrossRefPubMed

44.

Wang F, Chen W, Liu P, Zhou J, Liu B, Ye W, Wang W, Shen X (2017) Lentivirus-mediated RNAi knockdown of LMP2A inhibits the growth of the Epstein–Barr-associated gastric carcinoma cell line GT38 in vitro. Exp Ther Med 13(1):187–193. https://doi.org/10.3892/etm.2016.3954 CrossRefPubMed

45.

Wilson JB, Manet E, Gruffat H, Busson P, Blondel M, Fahraeus R (2018) EBNA1: oncogenic activity, immune evasion and biochemical functions provide targets for novel therapeutic strategies against Epstein–Barr virus-associated cancers. Cancers (Basel). https://doi.org/10.3390/cancers10040109 CrossRefPubMedCentral

46.

Reisman D, Yates J, Sugden B (1985) A putative origin of replication of plasmids derived from Epstein–Barr virus is composed of two cis-acting components. Mol Cell Biol 5(8):1822–1832. https://doi.org/10.1128/MCB.5.8.1822 CrossRefPubMedPubMedCentral

47.

Malik-Soni N, Frappier L (2014) Nucleophosmin contributes to the transcriptional activation function of the Epstein–Barr virus EBNA1 protein. J Virol 88(4):2323–2326. https://doi.org/10.1128/JVI.02521-13 CrossRefPubMedPubMedCentral

48.

Gahn T, Sugden B (1995) An EBNA1 dependent enhancer acts from a distance of 10 kilobase pairs to increase expression of the Epstein–Barr virus LMP gene. J Virol 69(4):2633–2636PubMedPubMedCentral

49.

Boreström C, Forsman A, Rüetschi U, Rymo L (2012) E2F1, ARID3A/Bright and Oct-2 factors bind to the Epstein–Barr virus C promoter, EBNA1 and oriP, participating in long-distance promoter-enhancer interactions. J Gen Virol 93(Pt 5):1065–1075. https://doi.org/10.1099/vir.0.038752-0 CrossRefPubMed

50.

Tempera I, De Leo A, Kossenkov AV, Cesaroni M, Song H, Dawany N et al (2015) Identification of MEF2B, EBF1, and IL6R as direct gene targets of Epstein–Barr virus (EBV) nuclear antigen 1 critical for EBV-infected B-lymphocyte survival. J Virol 90(1):345–355. https://doi.org/10.1128/JVI.02318-15 CrossRefPubMedPubMedCentral

51.

Kaiser C, Laux G, Eick D, Jochner N, Bornkamm GW, Kempkes B (1999) The proto-oncogene c-myc is a direct target gene of Epstein–Barr virus nuclear antigen 2. J Virol 73(5):4481–4484PubMedPubMedCentral

52.

Konforte D, Simard N, Paige CJ (2008) Interleukin-21 regulates expression of key Epstein–Barr virus oncoproteins, EBNA2 and LMPl, in infected human B cells. Virology 374(1):100–113. https://doi.org/10.1016/j.virol.2007.12.027 CrossRefPubMed

53.

Yokoyama A, Tanaka M, Matsuda G, Kato K, Kanamori M, Kawasaki H et al (2001) Identification of major phosphorylation sites of Epstein–Barr virus nuclear antigen leader protein (EBNA-LP): ability of EBNA-LP to induce latent membrane protein 1 cooperatively with EBNA-2 is regulated by phosphorylation. J Virol 75(11):5119–5128. https://doi.org/10.1128/JVI.75.11.5119-5128.2001 CrossRefPubMedPubMedCentral

54.

Kitay MK, Rowe DT (1996) Cell cycle stage-specific phosphorylation of the Epstein–Barr virus immortalization protein EBNA-LP. J Virol 70(11):7885–7893PubMedPubMedCentral

55.

Kato K, Yokoyama A, Tohya Y, Akashi H, Nishiyama Y, Kawaguchi Y (2003) Identification of protein kinases responsible for phosphorylation of Epstein–Barr virus nuclear antigen leader protein at serine-35, which regulates its coactivator function. J Gen Virol 84(Pt 12):3381–3392. https://doi.org/10.1099/vir.0.19454-0 CrossRefPubMed

56.

Tierney RJ, Kao KY, Nagra JK, Rickinson AB (2011) Epstein–Barr virus BamHI W repeat number limits EBNA2/EBNA-LP coexpression in newly infected B cells and the efficiency of B-cell transformation: a rationale for the multiple W repeats in wild-type virus strains. J Virol 85(23):12362–12375. https://doi.org/10.1128/JVI.06059-11 CrossRefPubMedPubMedCentral

57.

Szymula A, Palermo RD, Bayoumy A, Groves IJ, Ba Abdullah M et al (2018) Epstein–Barr virus nuclear antigen EBNA-LP is essential for transforming naïve B cells, and facilitates recruitment of transcription factors to the viral genome. PLoS Pathog 14(2):e1006890. https://doi.org/10.1371/journal.ppat.1006890 CrossRefPubMedPubMedCentral

58.

Bazot Q, Paschos K, Allday MJ (2018) Epstein–Barr virus (EBV) latent protein EBNA3A directly targets and silences the STK39 gene in B cells infected by EBV. J Virol. https://doi.org/10.1128/JVI.01918-17 CrossRefPubMedPubMedCentral

59.

Tursiella ML, Bowman ER, Wanzeck KC, Throm RE, Liao J, Zhu J, Sample CE (2014) Epstein–Barr virus nuclear antigen 3A promotes cellular proliferation by repression of the cyclin-dependent kinase inhibitor p21^WAF1/CIP1. PLoS Pathog 10(10):e1004415. https://doi.org/10.1371/journal.ppat.1004415 CrossRefPubMedPubMedCentral

60.

Bazot Q, Deschamps T, Tafforeau L, Siouda M, Leblanc P, Harth-Hertle ML et al (2014) Epstein–Barr virus nuclear antigen 3A protein regulates CDKN2B transcription via interaction with MIZ-1. Nucleic Acids Res 42(15):9700–9716. https://doi.org/10.1093/nar/gku697 CrossRefPubMedPubMedCentral

61.

Skalska L, White RE, Franz M, Ruhmann M, Allday MJ (2010) Epigenetic repression of p16 (INK4A) by latent Epstein–Barr virus requires the interaction of EBNA3A and EBNA3C with CtBP. PLoS Pathog 6(6):e1000951. https://doi.org/10.1371/journal.ppat.1000951 CrossRefPubMedPubMedCentral

62.

Bajaj BG, Murakami M, Cai Q, Verma SC, Lan K, Robertson ES (2008) Epstein–Barr virus nuclear antigen 3C interacts with and enhances the stability of the c-Myc oncoprotein. J Virol 82(8):4082–4090. https://doi.org/10.1128/JVI.02500-07 CrossRefPubMedPubMedCentral

63.

Shukla SK, Jha HC, El-Naccache DW, Robertson ES (2016) An EBV recombinant deleted for residues 130–159 in EBNA3C can deregulate p53/Mdm2 and Cyclin D1/CDK6 which results in apoptosis and reduced cell proliferation. Oncotarget 7(14):18116–18134. https://doi.org/10.18632/oncotarget.7502 CrossRefPubMedPubMedCentral

64.

Russell M, Berardi P, Gong W, Riabowol K (2006) Grow-ING, Age-ING and Die-ING: ING proteins link cancer, senescence and apoptosis. Exp Cell Res 312(7):951–961. https://doi.org/10.1016/j.yexcr.2006.01.020 CrossRefPubMed

65.

Soliman MA, Riabowol K (2007) After a decade of study-ING, a PHD for a versatile family of proteins. Trends Biochem Sci 32(11):509–519. https://doi.org/10.1016/j.tibs.2007.08.006 CrossRefPubMed

66.

Saha A, Bamidele A, Murakami M, Robertson ES (2011) EBNA3C attenuates the function of p53 through interaction with inhibitor of growth family proteins 4 and 5. J Virol 85(5): 2079–2088. https://doi.org/10.1128/JVI.02279-10 CrossRefPubMed

67.

Sahu SK, Mohanty S, Kumar A, Kundu CN, Verma SC, Choudhuri T (2014) Epstein–Barr virus nuclear antigen 3C interact with p73: Interplay between a viral oncoprotein and cellular tumor suppressor. Virology 448:333–343. https://doi.org/10.1016/j.virol.2013.10.023 CrossRefPubMed

68.

Johnson DG, Schwarz JK, Cress WD, Nevins JR (1993) Expression of transcription factor E2F1 induces quiescent cells to enter S phase. Nature 365(6444):349–352. https://doi.org/10.1038/365349a0 CrossRefPubMed

69.

Engelmann D, Pützer BM (2010) Translating DNA damage into cancer cell death-A roadmap for E2F1 apoptotic signalling and opportunities for new drug combinations to overcome chemoresistance. Drug Resist Updat 13(4–5):119–131. https://doi.org/10.1016/j.drup.2010.06.001 CrossRefPubMed

70.

Saha A, Lu J, Morizur L, Upadhyay SK, Aj MP, Robertson ES (2012) E2F1 mediated apoptosis induced by the DNA damage response is blocked by EBV nuclear antigen 3C in lymphoblastoid cells. PLoS Pathog 8(3):e1002573. https://doi.org/10.1371/journal.ppat.1002573 CrossRefPubMedPubMedCentral

71.

Pei Y, Banerjee S, Sun Z, Jha HC, Saha A, Robertson ES (2016) EBV nuclear antigen 3C mediates regulation of E2F6 to inhibit E2F1 transcription and promote cell proliferation. PLoS Pathog 12(8):e1005844. https://doi.org/10.1371/journal.ppat.1005844 CrossRefPubMedPubMedCentral

72.

Maruo S, Zhao B, Johannsen E, Kieff E, Zou J, Takada K (2011) Epstein–Barr virus nuclear antigens 3C and 3A maintain lymphoblastoid cell growth by repressing p16^INK4A and p14^ARF expression. Proc Natl Acad Sci U S A 108(5):1919–1924. https://doi.org/10.1073/pnas.1019599108 CrossRefPubMedPubMedCentral

73.

Rovedo M, Longnecker R (2007) Epstein–Barr virus latent membrane protein 2B (LMP2B) modulates LMP2A activity. J Virol 81(1):84–94. https://doi.org/10.1128/JVI.01302-06 CrossRefPubMed

74.

White RE, Rämer PC, Naresh KN, Meixlsperger S, Pinaud L et al (2012) EBNA3B-deficient EBV promotes B cell lymphomagenesis in humanized mice and is found in human tumors. J Clin Invest 122(4):1487–1502. https://doi.org/10.1172/JCI58092 CrossRefPubMedPubMedCentral

75.

Naseem M, Barzi A, Brezden-Masley C, Puccini A, Berger MD, Tokunaga R et al (2018) Outlooks on Epstein–Barr virus associated gastric cancer. Cancer Treat Rev 66:15–22. https://doi.org/10.1016/j.ctrv.2018.03.006 CrossRefPubMedPubMedCentral

76.

Vockerodt M, Yap LF, Shannon-Lowe C, Curley H, Wei W, Vrzalikova K, Murray PG (2015) The Epstein–Barr virus and the pathogenesis of lymphoma. J Pathol 235:312–322. https://doi.org/10.1002/path.4459 CrossRefPubMed

77.

Young LS, Dawson CW (2014) Epstein–Barr virus and nasopharyngeal carcinoma. Chin J Cancer 33(12):581–590. https://doi.org/10.5732/cjc.014.10197 CrossRefPubMedPubMedCentral

78.

Pai T, Gupta S, Gurav M, Nag S, Shet T, Patil A, Desai S (2018) Evidence for the association of Epstein–Barr virus in breast cancer in Indian patients using in-situ hybridization technique. Breast J 24(1):16–22. https://doi.org/10.1111/tbj.12828 CrossRefPubMed

79.

Herbert KM, Pimienta (2016) Consideration of Epstein–Barr virus-encoded noncoding RNAs EBER1 and EBER2 as a functional backup of viral oncoprotein latent membrane protein 1. MBio 7(1):e01926-15. https://doi.org/10.1128/mBio.01926-15 CrossRefPubMedPubMedCentral

80.

Komano J, Maruo S, Kurozumi K, Oda T, Takada K (1999) Oncogenic role of Epstein–Barr virus-encoded RNAs in Burkitt’s lymphoma cell line Akata. J Virol 73(12):9827–9831PubMedPubMedCentral

81.

Kobayashi M, Nakamura S, Shibata K, Sahara N, Shigeno K, Shinjo K et al (2005) Etodolac inhibits EBER expression and induces Bcl-2-regulated apoptosis in Burkitt’s lymphoma cells. Eur J Haematol 75(3):212–220. https://doi.org/10.1111/j.1600-0609.2005.00498.x CrossRefPubMed

82.

Yamamoto N, Takizawa T, Iwanaga Y, Shimizu N, Yamamoto N (2000) Malignant transformation of B lymphoma cell line BJAB by Epstein–Barr virus-encoded small RNAs. FEBS Lett 484(2):153–158. https://doi.org/10.1016/S0014-5793(00)02145-1 CrossRefPubMed

83.

Banerjee AS, Pal AD, Banerjee S (2013) Epstein–Barr virus-encoded small non-coding RNAs induce cancer cell chemoresistance and migration. Virology 443(2):294–305. https://doi.org/10.1016/j.virol.2013.05.020 CrossRefPubMed

84.

Pfeffer S, Zavolan M, Grässer FA, Chien M, Russo JJ, Ju J et al (2004) Identification of virus-encoded microRNAs. Science 304(5671):734–736. https://doi.org/10.1126/science.1096781 CrossRefPubMed

85.

Milián E, Prats E, Cairó JJ, Gòdia F, Vives J (2015) BHRF1 exerts an antiapoptotic effect and cell cycle arrest via Bcl-2 in murine hybridomas. J Biotechnol 209:58–67. https://doi.org/10.1016/j.jbiotec.2015.06.379 CrossRefPubMed

86.

Feederle R, Linnstaedt SD, Bannert H, Lips H, Bencun M, Cullen BR, Delecluse HJ (2011) A viral microRNA cluster strongly potentiates the transforming properties of a human herpesvirus. PLoS Pathog 7(2):e1001294. https://doi.org/10.1371/journal.ppat.1001294 CrossRefPubMedPubMedCentral

87.

Ma J, Nie K, Redmond D, Liu Y, Elemento O, Knowles DM, Tam W (2016) EBV-miR-BHRF1-2 targets PRDM1/Blimp1: potential role in EBV lymphomagenesis. Leukemia 30(3):594–604. https://doi.org/10.1038/leu.2015.285 CrossRefPubMed

88.

Lung RW, Tong JH, Sung YM, Leung PS, Ng DC, Chau SL et al (2009) Modulation of LMP2A expression by a newly identified Epstein–Barr virus-encoded microRNA miR-BART22. Neoplasia 11(11):1174–1184CrossRefPubMedPubMedCentral

89.

Lei T, Yuen KS, Xu R, Tsao SW, Chen H, Li M et al (2013) Targeting of DICE1 tumor suppressor by Epstein–Barr virus-encoded miR-BART3* microRNA in nasopharyngeal carcinoma. Int J Cancer 133(1):79–87. https://doi.org/10.1002/ijc.28007 CrossRefPubMed

90.

Kang D, Skalsky RL, Cullen BR (2015) EBV BART microRNAs target multiple pro-apoptotic cellular genes to promote epithelial cell survival. PLoS Pathog 11(6):e1004979. https://doi.org/10.1371/journal.ppat.1004979 CrossRefPubMedPubMedCentral

91.

Lu Y, Qin Z, Wang J, Zheng X, Lu J, Zhang X, Wei L et al (2017) Epstein–Barr virus miR-BART6-3p inhibits the RIG-I pathway. J Innate Immun 9(6):574–586. https://doi.org/10.1159/000479749 CrossRefPubMed

92.

Wong AM, Kong KL, Tsang JW, Kwong DL, Guan XY (2012) Profiling of Epstein–Barr virus-encoded microRNAs in nasopharyngeal carcinoma reveals potential biomarkers and oncomirs. Cancer 118(3):698–710. https://doi.org/10.1002/cncr.26309 CrossRefPubMed

93.

Zhao Z, Liu W, Liu J, Wang J, Luo B (2017) The effect of EBV on WIF1, NLK, and APC gene methylation and expression in gastric carcinoma and nasopharyngeal cancer. J Med Virol 89(10):1844–1851. https://doi.org/10.1002/jmv.24863 CrossRefPubMed

94.

Zhou L, Bu Y, Liang Y, Zhang F, Zhang H, Li S (2016) Epstein–Barr virus (EBV)-BamHI-A rightward transcript (BART)-6 and cellular microRNA-142 synergistically compromise immune defense of host cells in EBV-positive Burkitt lymphoma. Med Sci Monit 22:4114–4120. https://doi.org/10.12659/MSM.897306 CrossRefPubMedPubMedCentral

95.

Vereide DT, Seto E, Chiu YF, Hayes M, Tagawa T, Grundhoff A et al (2014) Epstein–Barr virus maintains lymphomas via its miRNAs. Oncogene 33(10):1258–1264. https://doi.org/10.1038/onc.2013.71 CrossRefPubMed

96.

Qiu J, Smith P, Leahy L, Thorley-Lawson DA (2015) The Epstein–Barr virus encoded BART miRNAs potentiate tumor growth in vivo. PLoS Pathog 11(1), e1004561. https://doi.org/10.1371/journal.ppat.1004561 CrossRefPubMedPubMedCentral

97.

Hooykaas MJG, van Gent M, Soppe JA, Kruse E, Boer IGJ, van Leenen D et al (2017) EBV microRNA BART16 suppresses type I IFN signaling. J Immunol 198(10):4062–4073. https://doi.org/10.4049/jimmunol.1501605 CrossRefPubMed

98.

Lung RW, Hau PM, Yu KH, Yip KY, Tong JH, Chak WP et al (2018) EBV-encoded miRNAs target ATM-mediated response in nasopharyngeal carcinoma. J Pathol 244(4):394–407. https://doi.org/10.1002/path.5018 CrossRefPubMedPubMedCentral

Title: Molecular mechanisms of EBV-driven cell cycle progression and oncogenesis
Authors: Huali Yin
Jiani Qu
Qiu Peng
Runliang Gan
Publication date: 01-10-2019
Publisher: Springer Berlin Heidelberg
Published in: Medical Microbiology and Immunology / Issue 5/2019
Print ISSN: 0300-8584
Electronic ISSN: 1432-1831
DOI: https://doi.org/10.1007/s00430-018-0570-1

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2019

Interaction of host and Staphylococcus aureus protease-system regulates virulence and pathogenicity

Identification of complement-related host genetic risk factors associated with influenza A(H1N1)pdm09 outcome: challenges ahead

Immune response triggered by Trypanosoma cruzi infection strikes adipose tissue homeostasis altering lipid storage, enzyme profile and adipokine expression

Different roles of CXCR1 and CXCR2 in HTLV-1 carriers and HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) patients

Increased SAMHD1 transcript expression correlates with interferon-related genes in HIV-1-infected patients

The monocytosis during human leptospirosis is associated with modest immune cell activation states

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage